Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: Comparison with caplet formulation

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 5, 2005, Pages 492-496

  Muindi, Josephia R ^a   Potter, Douglas M ^b   Peng, Yibing ^b   Johnson, Candace S ^a   Trump, Donald L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer patients; Liquid calcitriol formulation; Serum pharmacokinetics

Indexed keywords

CALCITRIOL; DEXAMETHASONE; PACLITAXEL;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EXPOSURE; DRUG FORMULATION; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; INTERMETHOD COMPARISON; LIQUID; MUSCLE WEAKNESS; NAUSEA; PRIORITY JOURNAL; SAMPLE SIZE; SOLID TUMOR; VOMITING;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CAPSULES; DEXAMETHASONE; DIARRHEA; HUMANS; MALE; PACLITAXEL; PHARMACEUTICAL SOLUTIONS; PROSTATIC NEOPLASMS;

EID: 27644521288     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1015-2     Document Type: Article

References (23)

1. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinol 108:1083-1086
2. 3inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem 24:373-376
3. Cross HS, Pavelka M, Slavik J, Peterlik M (1992) Growth control of human colon cancer cells by vitamin D and calcium in vitro. J Natl Cancer Inst 84:1355-1357
4. 3 on primary cultures of human prostatic cells. Cancer Res 54:805-810
5. 3 analogue in a squamous cell carcinoma model system. Mol Cell Differ 3:31-50
6. 3. Cancer Res 47:21-25
7. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS Jr et al (1997) Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urol 50:999-1006
8. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS (1999) 1,25-dihydroxycholecalciferal (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21 (waf1/Cip1) in vitro and in vivo, Cancer Res 59:2644-2649
9. 3 leads to induced differentiation of myelomonocytic cell line U937. Gene Dev 10:142-153
10. 3 in HL60 cells. Cancer Res 56:264-267
11. 3-induced apoptosis of murine squamous cell carcinoma cells: Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 276:26365-26373
12. 3 with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 7:4164-4173
13. Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ et al (2002) Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 10:821-829
14. Wang X, Studzinski GP (2001) Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J Cell Biochem 80:471-82
15. 3-untreated antitumor activity with dexamethasone. J Natl Cancer Inst 90:134-141
16. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ et al (2002) Pharmacokinetics of high dose calcitriol: results obtained during a phase one trial of calcitriol and paclitaxel. Cancer Pharmacol Ther 72:648-659
17. Smith, DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL (1999) A phase I trial of Calcitriol (1,25-dihydroxycholecalciferal) in patients with advanced malignancy. Clin Cancer Res 5:1339-1345
18. Beer TM, Munar M, Henner WD (2001) A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 91:2431-2439
19. Tallarida RJ, Murray RB (1986) Manual of pharmacologic calculation with computer programs. Springer, Berlin Heidelberg New York, pp 197-291
20. Muindi JR, Modezlewski RA, Peng Y, Trump DL, Johnson CS (2004) Pharmacokinetics of 1α, 25-dihydroxycholecalciferol pharmacokinetics in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 66:62-66
21. Beer TM, Javle M, Henner WD, Trump DL (2004) Pharmacokinetics (PK) and tolerability of DN-101, a new formulation of calcitriol. Proc Am Assoc Cancer 95:404
22. Beer TM, Lemmon D, Lowe BA, Henner WD (2003) High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97:1217-1224
23. 2vitamin D3) + dexamethasone in androgen independent prostate cancer (AIPC). Am Soc Clin Oncol 19:337a